Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Revenue of Karyopharm Therapeutics Inc. (KPTI)
Revenue in 2023 (TTM): $146.03 M
According to Karyopharm Therapeutics Inc.'s latest financial reports the company's current revenue (TTM) is $146.03 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Karyopharm Therapeutics Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $146.03 M | $141.09 M | $-118,423,000 | $-142,776,000 | $-143,099,000 |
| 2022 | $157.07 M | $151.86 M | $-139,305,000 | $-164,922,000 | $-165,291,000 |
| 2021 | $209.82 M | $206.42 M | $-96,985,000 | $-123,820,000 | $-124,088,000 |
| 2020 | $108.09 M | $105.38 M | $-167,852,000 | $-195,964,000 | $-196,273,000 |
| 2019 | $40.89 M | $38.49 M | $-182,929,000 | $-199,550,000 | $-199,590,000 |
| 2018 | $30.34 M | $-131,036,000 | $-175,153,000 | $-178,381,000 | $-178,407,000 |
| 2017 | $1.61 M | $-105,668,000 | $-128,208,000 | $-128,921,000 | $-128,984,000 |
| 2016 | $154 K | $-86,784,000 | $-108,721,000 | $-109,438,000 | $-109,577,000 |
| 2015 | $250 K | $-97,494,000 | $-118,442,000 | $-118,181,000 | $-118,181,000 |
| 2014 | $229 K | $-59,898,000 | $-75,454,000 | $-75,777,000 | $-75,777,000 |
| 2013 | $387 K | $-28,065,000 | $-33,803,000 | $-33,947,000 | $-33,947,000 |
| 2012 | $634 K | $-13,461,000 | $-15,766,000 | $-15,888,000 | $-15,888,000 |
| 2011 | $152 K | $152 K | $-10,228,000 | $-10,311,000 | $-10,311,000 |